BiotechTube

Omadacycline + Moxifloxacin

Phase 3Recruiting
1 views this week 0 watching⚡ Active
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Community-acquired Bacterial Pneumonia

Conditions

Community-acquired Bacterial Pneumonia

Trial Timeline

Nov 17, 2023 → Nov 30, 2025

NCT ID
NCT06162286

About Omadacycline + Moxifloxacin

Omadacycline + Moxifloxacin is a phase 3 stage product being developed by Zai Lab for Community-acquired Bacterial Pneumonia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06162286. Target conditions include Community-acquired Bacterial Pneumonia.

What happened to similar drugs?

1 of 7 similar drugs in Community-acquired Bacterial Pneumonia were approved

Approved (1) Terminated (0) Active (6)
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
🔄Ceftaroline + CeftriaxonePfizerPhase 3
🔄Azithromycin microspheres 2.0 single dosePfizerPhase 3
🔄Azithromycin SRPfizerPhase 3
🔄tigecyclinePfizerPhase 3
🔄Tigecycline + LevofloxacinPfizerPhase 3
🔄ceftobiprole medocaril + IV standard-of-care cephalosporinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06162286Phase 3Recruiting

Competing Products

9 competing products in Community-acquired Bacterial Pneumonia

See all competitors
ProductCompanyStageHype Score
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
35
Ceftaroline + CeftriaxonePfizerPhase 3
40
Azithromycin microspheres 2.0 single dosePfizerPhase 3
40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
43
Azithromycin SRPfizerPhase 3
40
Azithromycin SR + AmoxiclavPfizerPre-clinical
18
tigecyclinePfizerPhase 3
40
Tigecycline + LevofloxacinPfizerPhase 3
40
ceftobiprole medocaril + IV standard-of-care cephalosporinBasilea PharmaceuticaPhase 3
34